Weill Cornell Graduate School of Medical Sciences

Weill Cornell Medicine to Expand in Midtown East Manhattan

Retrieved on: 
Monday, October 30, 2023
Commercial Building & Real Estate, Research, Construction & Property, Hospitals, Other Health, Managed Care, Health, General Health, Science, Education, NewYork-Presbyterian Queens, Houston Methodist Hospital, Heart, Physician, Grand Central Terminal, Medicine, Growth, Weill Cornell Medical Center, Weill Cornell Medicine, Weill Cornell Graduate School of Medical Sciences, Cornell University, NewYork-Presbyterian Brooklyn Methodist Hospital, Patient, Hospital, Midtown Manhattan, NewYork-Presbyterian Hospital

Weill Cornell Medicine is expanding its real estate agreement at 575 Lexington Ave. to provide state-of-the-art clinical care at the Midtown Manhattan location by 2025.

Key Points: 
  • Weill Cornell Medicine is expanding its real estate agreement at 575 Lexington Ave. to provide state-of-the-art clinical care at the Midtown Manhattan location by 2025.
  • The doctors and scientists of Weill Cornell Medicine—faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organization—are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies.
  • Located in the heart of the Upper East Side’s scientific corridor, Weill Cornell Medicine’s powerful network of collaborators extends to its parent university Cornell University; to Qatar, where Weill Cornell Medicine-Qatar offers a Cornell University medical degree; and to programs in Tanzania, Haiti, Brazil, Austria and Turkey.
  • Weill Cornell Medicine faculty provide exemplary patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian Westchester Behavioral Health Center, NewYork-Presbyterian Lower Manhattan Hospital, NewYork-Presbyterian Queens and NewYork-Presbyterian Brooklyn Methodist Hospital.

Weill Cornell Medicine Announces New Residence for Graduate and Medical Students, Expanding Scope of Upper East Side Campus

Retrieved on: 
Tuesday, October 17, 2023
Research, Commercial Building & Real Estate, Construction & Property, Hospitals, Philanthropy, General Health, Fund Raising, Health, Science, Residential Building & Real Estate, Multimedia, Weill Cornell Medicine, Physician, Medicine, Student, Houston Methodist Hospital, Weill Cornell Medical Center, Air conditioning, NewYork-Presbyterian Brooklyn Methodist Hospital, New Residence, South Australia, Socialization, Heart, Recreation, Cornell University, LEED, Patient, Education, Water, York Avenue and Sutton Place, NewYork-Presbyterian Queens, 74th Street (Manhattan), Weill Cornell Graduate School of Medical Sciences, Overalls, Biophysical environment, Ventilation, Gold, Graduate, Yoga, Atmosphere, Hospital, Interior design, NewYork-Presbyterian Hospital

Weill Cornell Medicine is constructing a modern new student residence that, when it opens in 2025, will expand the scope of the institution’s Upper East Side campus and nearly double the existing student residential living space.

Key Points: 
  • Weill Cornell Medicine is constructing a modern new student residence that, when it opens in 2025, will expand the scope of the institution’s Upper East Side campus and nearly double the existing student residential living space.
  • The future of Weill Cornell Medicine is bright.”
    “For more than a century, Weill Cornell Medicine has prided itself on producing exemplary doctors and researchers who have transformed our understanding and practice of medicine,” said Cornell President Martha E. Pollack.
  • The doctors and scientists of Weill Cornell Medicine—faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organization—are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies.
  • Weill Cornell Medicine faculty provide exemplary patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian Westchester Behavioral Health Center, NewYork-Presbyterian Lower Manhattan Hospital, NewYork-Presbyterian Queens and NewYork-Presbyterian Brooklyn Methodist Hospital.

Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation

Retrieved on: 
Tuesday, August 1, 2023
Infection, Neuron, DNA, BS, Optimism, University, University of California, Berkeley, Lyme disease, Doctor of Philosophy, Schizophrenia, Medicine, Curriculum, University of Maryland, College Park, Biomedical Research, University of Pennsylvania, Ginny Klevorn, Brain, Science, History of the University of Maryland, College Park, Protein, Publication, Patient, UC, Immune system, Weill Cornell Graduate School of Medical Sciences, Biological engineering, Pathogenesis, Pharmaceutical industry, Management, Regeneron Pharmaceuticals, Chemistry, Research

TARRYTOWN, N.Y., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 11th annual Regeneron Prize for Creative Innovation, a competition designed to honor exceptional talent and originality in biomedical research.

Key Points: 
  • TARRYTOWN, N.Y., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 11th annual Regeneron Prize for Creative Innovation, a competition designed to honor exceptional talent and originality in biomedical research.
  • Casey and Thaís will be honored as co-recipients of the prize in the graduate student category, with each receiving $25,000.
  • Additionally, five finalists were awarded $5,000 each, and each of the winners’ institutions received a $5,000 grant, resulting in $140,000 distributed in total.
  • “The Regeneron Prize recognizes and rewards creativity as a bedrock of impactful science.

SK-II UNVEILS SKIN AGING DISCOVERIES AT THE WORLD CONGRESS OF DERMATOLOGY 2023 AND INAUGURATES THE PITERA™ SCIENCE EXPERT PANEL

Retrieved on: 
Wednesday, July 19, 2023
Trigger, Cream, SK-II, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Beth Israel Deaconess Medical Center, AT-02, Weill Cornell Graduate School of Medical Sciences, Medicine, DEPT, Physician, Postgraduate education, Ageing, Kyushu University, Research, Associate, Science, Harvard Medical School, Congress, Professor, Kyoto University, MPH, Human, Skin, Cosmetics, Pharmaceutical industry, Management, Dermatology, MD

SINGAPORE, July 19, 2023 /PRNewswire/ -- Pushing the boundaries of skin aging science and innovations, global prestige skincare brand SK-II debuts new skin aging discoveries and innovations and inaugurates its first PITERA™ Science Expert Panel with some of the world's leading dermatologists. 

Key Points: 
  • SINGAPORE, July 19, 2023 /PRNewswire/ -- Pushing the boundaries of skin aging science and innovations, global prestige skincare brand SK-II debuts new skin aging discoveries and innovations and inaugurates its first PITERA™ Science Expert Panel with some of the world's leading dermatologists.
  • A pioneering longitudinal 10-year Akita Study and the PITERA™ 24/7 Skin Fluctuation Study on young skin has contributed to PITERA™ breakthroughs on skin.
  • If left untreated, the aging chain reaction can lead to accelerated aging signs, resulting in more severe signs of premature aging.
  • Following the World Congress of Dermatology, SK-II inaugurates its first-ever PITERA™ Science Expert Panel in recognition of some of the world's foremost dermatologists who have partnered with SK-II to advance skin aging science.

CHARM Therapeutics Strengthens Leadership Team with Key Appointments to Support Drug Discovery and Development Capability

Retrieved on: 
Wednesday, January 4, 2023
Biomedicine, Hoffmann-La Roche, Khosla Ventures, Stanford University, D, Machine learning, Roivant Sciences, Agios Pharmaceuticals, Pfizer, Doctor of Philosophy, Drug discovery, Head, Research, General Catalyst, Publication, Biology, Master of Science, Medicine, The Tumor, University of Minnesota College of Food, Agricultural and Natural Resource Sciences, Intelligence, AMAG Pharmaceuticals, ARIAD Pharmaceuticals, 3D, Therapy, Drug development, Vertex, Deep learning, GSK, Toxicology, University, Family, Cancer Research UK, Cell, Senior, Weill Cornell Graduate School of Medical Sciences, Pharmacokinetics, Merck & Co., MBA, Data management, Moscow State University, Immersion, DPU, Medical device, Pharmaceutical industry, Management, Crystallography, Science, Health care, Economics, Pharmacology, AI, Nature

LONDON – 4 January 2023 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research Company discovering and developing transformational medicines, today announces the expansion of its leadership team with a series of key appointments to strengthen its drug discovery and development, as well as operational management capabilities.

Key Points: 
  • Enhanced leadership team brings strong AI and drug discovery expertise and experience, reinforcing CHARM Therapeutics’ existing R&D capabilities
    LONDON – 4 January 2023 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research Company discovering and developing transformational medicines, today announces the expansion of its leadership team with a series of key appointments to strengthen its drug discovery and development, as well as operational management capabilities.
  • These appointments will support CHARM as it builds out of its research and development function to advance discoveries driven by its proprietary 3D deep-learning engine towards development.
  • CHARM Therapeutics raised $50 million in a Series A financing round announced in 2022, led by F-Prime Capital and OrbiMed, with General Catalyst and Khosla Ventures.
  • Gary D. Glick Ph.D., Executive Chair of CHARM Therapeutics, commented: “The exceptional people joining CHARM bring the perfect combination of skills, from immersion in AI, oncology and translational research to long experience in organizational leadership.

Study Reports Similar Efficacy of Dynamic Digital Radiography of the Chest with Lung Ventilation Perfusion for Detection of Chronic Thromboembolic Pulmonary Hypertension

Retrieved on: 
Tuesday, November 22, 2022
Doctor of Philosophy, Editorial, Medicine, WHO, Diagnosis, Lung, Society for Imaging Science and Technology, University, DCR, Nuclear medicine, Digital radiography, Physician, Mortality, Patient, Agent handling, Comment, Radiological Society of North America, Graduate school, MD, Disease, World Health Organization, MRI, Pulmonary hypertension, Senior, Innovation, Weill Cornell Graduate School of Medical Sciences, University of Rochester Medical Center, Assistant, Konica Minolta, Pulmonary embolism, Research, CTEPH, Motion, Kyushu University, CT, DDR, Medical imaging, Marketing, Radiology

Dynamic Digital Radiography is a radiographic technique that provides a series of individual digital X-ray images acquired at high speed and low radiation dose.

Key Points: 
  • Dynamic Digital Radiography is a radiographic technique that provides a series of individual digital X-ray images acquired at high speed and low radiation dose.
  • CTEPH is a complication of pulmonary embolism and a significant cause of pulmonary hypertension with associated morbidity and mortality if left untreated.
  • As a potentially treatable cause of pulmonary hypertension, identification of CTEPH with imaging may significantly impact clinical outcomes of patients with this condition.
  • Each patient also had conventional chest radiography and underwent a lung V/Q study on a SPECT/CT system with intravenous injection of technetium-99m macroaggregated albumin, 185 MBq.

Orionis Biosciences Secures $55 Million Financing to Support Advancement into Clinic

Retrieved on: 
Wednesday, October 19, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Wharton School of the University of Pennsylvania, Doctor of Philosophy, Molecular biology, Therapy, Indiana State University, University college, Growth, Bristol Myers Squibb, Drug development, Weill Cornell Graduate School of Medical Sciences, Genetic engineering, MBA, List of life sciences, Ohio State University College of Medicine, FU Orionis, Medicine, Investment, Cancer, Precision medicine, University, Graduate school, Drug discovery, Industry, Novartis, Board, CEO, Immunotherapy, Weill Cornell Medicine, Financial toxicity, Genetics, Fudan University, FDA, Management, Pharmaceutical industry

Founded in 2015, Orionis has since developed its proprietary technology platforms, grown a deep pipeline and cemented a drug discovery deal with Novartis.

Key Points: 
  • Founded in 2015, Orionis has since developed its proprietary technology platforms, grown a deep pipeline and cemented a drug discovery deal with Novartis.
  • This latest financing round provides the company with additional capital for R&D expansion, pipeline growth and advancement of its lead cancer immunotherapy programs into clinical trials.
  • Existing and new investors participated in the round, including Cormorant Asset Management, Novartis and a series of high-caliber investment funds.
  • In addition, we are pleased to welcome industry veteran Bihua Chen to our Board as we enter this next stage of growth.

Regeneron Elects Dr. Craig B. Thompson to Board of Directors

Retrieved on: 
Monday, October 3, 2022
Degenerative disease, Cancer, NASDAQ, National, Heart, Inflammation, Weill Cornell Graduate School of Medical Sciences, National academy, Drug development, Physician, MSK, Regeneron Pharmaceuticals, University, Memorial Sloan Kettering Cancer Center, Immunotherapy, Lists of diseases, Disease, Precision medicine, Research, Gene, Health, Hematology, CEO, Twitter, Internal medicine, Pain, Fred Hutchinson Cancer Research Center, Parliamentary Information Technology Committee, Brigham and Women's Hospital, FDA, Monoclonal antibody, Antibody, Sloan, Medicine, Harvard Medical School, Eye, Infection, Teaching hospital, NAS, Bachelor, Allergy, Biotechnology, Director, Patient, Laboratory, Center, Board of directors, Board, Management, Pharmaceutical industry, Vaccine, Science

TARRYTOWN, N.Y., Oct. 3, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Craig B. Thompson, M.D., has been elected to the Board of Directors, effective immediately. Dr. Thompson has also been appointed to serve on the Technology Committee of the Regeneron Board. Dr. Thompson is a renowned healthcare business leader with exceptional senior executive experience and scientific expertise in multiple therapeutic areas, including oncology. Regeneron's Board of Directors has been expanded from 12 to 13 members with the addition of Dr. Thompson.

Key Points: 
  • Dr. Thompson has also been appointed to serve on the Technology Committee of the Regeneron Board.
  • Regeneron's Board of Directors has been expanded from 12 to 13 members with the addition of Dr. Thompson.
  • Dr. Thompson has been heavily involved in research throughout his career, particularly in the cutting-edge fields of immunotherapy and precision medicine.
  • "We are thrilled to welcome Dr. Thompson to our Board," said P. Roy Vagelos, M.D., Chairman of the Regeneron Board of Directors.

Serotiny Appoints Chad May, Ph.D., as Chief Scientific Officer

Retrieved on: 
Monday, May 23, 2022
Oncology, Health, Genetics, General Health, Pharmaceutical, Biotechnology, Cell biology, Knowledge, Engineering, Center for Research and Development in Health Sciences, Doctor of Philosophy, Weill Cornell Graduate School of Medical Sciences, Maverick, Leadership, Patient, Synthetic biology, Medicine, Sloan, Canadian Aviation Regulations, IND, TMDP, Chimeric antigen receptor T cell, Takeda, Protein, University, Technology, Chad, Eli Lilly, Heart, Machine learning, ImClone Systems, Medical device, Vaccine, Immunology, Serotiny, Research, Pfizer, Genetics

Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering for the next generation of cell and gene therapies, has appointed Chad May, Ph.D., as the company's Chief Scientific Officer.

Key Points: 
  • Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering for the next generation of cell and gene therapies, has appointed Chad May, Ph.D., as the company's Chief Scientific Officer.
  • In this new role, Dr. May will lead the research and development of Serotinys novel therapeutics programs.
  • "Chad is a fantastic addition to the Serotiny leadership team," said Serotiny Chief Executive Officer Colin Farlow.
  • Dr. May commented, "It is very exciting for me to be joining the innovative team at Serotiny.

Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs

Retrieved on: 
Thursday, March 31, 2022
Cancer, Therapy, Drug development, LinkedIn, Biochemistry, Regulatory affairs, Ultragenyx, BioMarin Pharmaceutical, Trial of the century, Forward-looking statement, Elosulfase alfa, Patient, California State University, Fresno, Enzyme replacement therapy, Weill Cornell Graduate School of Medical Sciences, Biotechnology, Program, Memorial, California State University, CEO, MPS, Lymphatic system, Doctor of Philosophy, Medicine, NDA, 4A, Lists of diseases, C/EBP, Pharmaceutical industry, Wisdom, Pharmacology

HARRISON, N.Y., March 31, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today the appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs.

Key Points: 
  • HARRISON, N.Y., March 31, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today the appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs.
  • Dr. Capiaux has a long-standing career in the biotechnology and pharmaceutical industry, holding several senior level positions at notable companies.
  • Sapience Therapeutics, Inc. is a privately held, clinical stage biotechnology company focused on discovering and developing peptide therapeutics for major unmet medical needs, particularly high mortality cancers.
  • For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com and engage with us on LinkedIn .